Around 25% of US venture capital biopharma investments flowed to Massachusetts in 2022: cementing the state’s position as a leader in the industry. But how will economic uncertainty affect the hub’s fortunes moving forward?
Sanofi Ventures has announced an additional multi-year commitment from Sanofi, with an increase in capital to more than $750m to the evergreen venture fund.
V-Bio Ventures, a venture capital firm supporting young pioneering biotech companies raises €110m (US$122m) in its second fund, V-Bio Fund 2, exceeding its target of €100m.
Last year was the highest year on record for investments into UK biotech and life science companies: with £4.5bn ($6bn) raised in public and private financings, representing 60% more than in 2020.
Culture Biosciences, a company enabling biotech firms to develop and scale manufacturing processes in the cloud, recently announced an $80m Series B round, taking the funds it has raised to date to $100m+.
Biotech funding kicked back into higher gear in October, pushing toward the summer monthly record highs with $10.5B raised, writes analyst firm, Jefferies
Ori Biotech Ltd (Ori), a London and New Jersey based innovator in the cell and gene therapy (CGT) manufacturing sphere, last week announced the successful close of a US$30m Series A financing round, bringing the company’s total funding to date to US$41m.
Chinese investors are looking abroad for technology that will provide short-term returns and long-term health benefits to its large patient population, according to Panacea Ventures partner.
Catalent says it is contemplating expanding its Wisconsin single-use biologics facility as strong demand from SMEs and biotechs has almost filled current capacity.
The UK’s BioCity in Nottingham is adding a £30m ($47m) facility to house life science start-ups including CROs. The site will also become a hunting ground for a soon-to-launch venture capital fund which will invest in the SME tenants.
Lonza saw profits and capacity utilisation improve in the first half of 2014 with new pharma and biopharma supply contracts and ongoing restructuring being the key drivers.
